A cardiopulmonary resuscitation compression force indicator

Details for Australian Patent Application No. 2007331664 (hide)

Owner HEARTSINE TECHNOLOGIES LIMITED

Inventors McIntyre, Allister R.; Anderson, Johnny Houston; Allen, James; Anderson, John McCune

Agent Griffith Hack

Pub. Number AU-A-2007331664

PCT Pub. Number WO2008/071439

Priority S2006/0916 14.12.06 IE

Filing date 14 December 2007

Wipo publication date 19 June 2008

International Classifications

A61B 5/00 (2006.01) Measuring for diagnostic purposes

A61B 5/053 (2006.01) Measuring for diagnostic purposes - Measuring electrical impedance or conductance of a portion of the body

A61N 1/39 (2006.01) Electrotherapy - Heart defibrillators

A61B 5/08 (2006.01) Measuring for diagnostic purposes - Measuring devices for evaluating the respiratory organs

Event Publications

30 July 2009 PCT application entered the National Phase

  PCT publication WO2008/071439 Priority application(s): WO2008/071439

21 July 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

18 August 2011 Section 223 Application Allowed

  HEARTSINE TECHNOLOGIES LIMITED The time in which to request examination has been extended to 21 Aug 2011. Address for service in Australia - Griffith Hack Level 3 509 St Kilda Road Melbourne VIC 3004 2009

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007331669-Monitoring device

2007331663-Treatment of disease or injury of the nervous system using agents that decrease the activity of the melanocortin 4 receptor